

Alnylam Pharmaceuticals, Inc.

Reconciliation of Selected GAAP Measures to Non-GAAP Measures (In thousands, except per share amounts)

| | Three Months Ended September 30, | | | | Nine Months Ended September 30, | | | |
|---|-------------------------------------|-----------|------|-----------|------------------------------------|-----------|------|-----------|
| Reconciliation of GAAP to Non-GAAP Research and Development: | 2019 | | 2018 | | 2019 | | 2018 | |
| GAAP Research and Development | \$ | 160,796 | \$ | 139,945 | \$ | 453,813 | \$ | 374,384 |
| Less: Stock-Based Compensation Expenses | | (22,737) | | (45,784) | | (54,144) | | (67,537) |
| Non-GAAP Research and Development | \$ | 138,059 | \$ | 94,161 | \$ | 399,669 | \$ | 306,847 |
| Reconciliation of GAAP to Non-GAAP Selling, General and Administrative: | | | | | | | | |
| GAAP Selling, General and Administrative | \$ | 120,351 | \$ | 116,545 | \$ | 322,728 | \$ | 273,671 |
| Less: Stock-Based Compensation Expenses | | (23,272) | | (42,170) | | (54,500) | | (62,242) |
| Non-GAAP Selling, General and Administrative | \$ | 97,079 | \$ | 74,375 | \$ | 268,228 | \$ | 211,429 |
| Reconciliation of GAAP to Non-GAAP Operating Expenses: | | | | | | | | |
| GAAP Operating Expenses | \$ | 286,360 | \$ | 256,627 | \$ | 789,427 | \$ | 648,192 |
| Less: Stock-Based Compensation Expenses | | (46,009) | | (87,954) | | (108,644) | | (129,779) |
| Non-GAAP Operating Expenses | \$ | 240,351 | \$ | 168,673 | \$ | 680,783 | \$ | 518,413 |
| Reconciliation of GAAP to Non-GAAP Net Loss: | | | | | | | | |
| GAAP Net Loss | \$ | (208,535) | \$ | (245,282) | \$ | (609,931) | \$ | (550,056) |
| Add: Stock-Based Compensation Expenses | | 46,009 | | 87,954 | | 108,644 | | 129,779 |
| Less: Change in Fair Value of Liability Obligation | | - | | - | | (9,422) | | - |
| Less: Gain on Litigation Settlement | | - | | - | | - | | (20,564) |
| Non-GAAP Net Loss | \$ | (162,526) | \$ | (157,328) | \$ | (510,709) | \$ | (440,841) |
| Reconciliation of GAAP to Non-GAAP Net Loss per Common Share - Basic and Diluted: | | | | | | | | |
| GAAP Net Loss per Common Share - Basic and Diluted | \$ | (1.92) | \$ | (2.43) | \$ | (5.63) | \$ | (5.48) |
| Add: Stock-Based Compensation Expenses | | 0.42 | | 0.87 | | 1.01 | | 1.29 |
| Less: Change in Fair Value of Liability Obligation | | - | | - | | (0.09) | | - |
| Less: Gain on Litigation Settlement | | | | | | | | (0.20) |
| Non-GAAP Net Loss per Common Share - Basic and Diluted | \$ | (1.50) | \$ | (1.56) | \$ | (4.71) | \$ | (4.39) |